Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis

NCT02990806 is registered in ClinicalTrials.gov with Nichi-Iko Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02990806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02990806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Lead sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 19, 2017
Completion date
May 20, 2019
Enrollment
683 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis